Peregrine Capital Management LLC Trims Holdings in ADMA Biologics Inc (NASDAQ:ADMA)

Peregrine Capital Management LLC trimmed its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 7.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 403,141 shares of the biotechnology company's stock after selling 33,056 shares during the quarter. Peregrine Capital Management LLC owned 0.17% of ADMA Biologics worth $7,998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. New York State Teachers Retirement System boosted its holdings in ADMA Biologics by 96.2% in the first quarter. New York State Teachers Retirement System now owns 221,890 shares of the biotechnology company's stock worth $4,402,000 after acquiring an additional 108,800 shares in the last quarter. KBC Group NV raised its position in shares of ADMA Biologics by 11.5% in the 1st quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock valued at $223,000 after purchasing an additional 1,154 shares during the last quarter. Lisanti Capital Growth LLC boosted its stake in ADMA Biologics by 75.8% in the 1st quarter. Lisanti Capital Growth LLC now owns 308,440 shares of the biotechnology company's stock worth $6,119,000 after purchasing an additional 132,970 shares in the last quarter. Tsfg LLC purchased a new stake in ADMA Biologics during the 1st quarter worth approximately $51,000. Finally, Allspring Global Investments Holdings LLC increased its stake in ADMA Biologics by 7.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock valued at $59,211,000 after purchasing an additional 207,097 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ADMA. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial boosted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th.

ADMA Biologics Price Performance

NASDAQ ADMA traded up $0.16 on Thursday, hitting $18.30. The company had a trading volume of 1,053,349 shares, compared to its average volume of 3,693,451. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The company's fifty day moving average price is $20.40 and its 200-day moving average price is $18.73. The company has a market capitalization of $4.37 billion, a PE ratio of 21.52 and a beta of 0.43. ADMA Biologics Inc has a 12-month low of $10.21 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. The company had revenue of $114.80 million during the quarter, compared to analyst estimates of $116.40 million. During the same quarter last year, the business earned $0.08 EPS. The firm's revenue for the quarter was up 40.2% compared to the same quarter last year. As a group, analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the transaction, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This represents a 17.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 464,621 shares of company stock valued at $9,644,269 over the last ninety days. Insiders own 3.50% of the company's stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.